Want to see SE:EGTX full AI Analyst Report?
Egetis Therapeutics AB (EGTX) Income Statement
Egetis Therapeutics AB Income Statement
Last quarter (Q2 2026), Egetis Therapeutics AB's total revenue was $17.40M, an increase of 20.00% from the same quarter last year. In Q2, Egetis Therapeutics AB's net income was $-108.90M. See Egetis Therapeutics AB’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 62.40M | $ 46.10M | $ 57.60M | $ 22.50M | $ 38.24M | |
| $ 12.40M | $ 34.50M | $ -146.90M | $ -120.10M | $ -58.28M | |
| $ 359.30M | $ 363.90M | $ 177.90M | $ 54.70M | $ 46.80M | |
| Depreciation and Amortization | $ 3.70M | $ 0.00 | $ 3.60M | $ 2.70M | $ 2.46M |
| $ -343.20M | $ -317.30M | $ -319.10M | $ -191.00M | $ -101.90M | |
| $ -346.90M | $ -329.40M | $ -324.80M | $ -198.10M | $ -105.68M | |
| $ 4.80M | $ -13.80M | $ -2.00M | $ 4.30M | $ 1.18M | |
| $ -342.10M | $ -343.20M | $ -326.80M | $ -193.80M | $ -104.54M | |
| $ -342.50M | $ -343.60M | $ -326.90M | $ -189.50M | $ -104.73M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.93 | $ -1.12 | $ -1.27 | $ -0.98 | $ -0.58 |
| Diluted EPS | $ -0.93 | $ -1.12 | $ -1.26 | $ -0.98 | $ -0.58 |
| Weighted Average Shares Outstanding | 368.19M | 306.54M | 256.75M | 194.24M | 179.91M |
| Weighted Average Shares Outstanding (Diluted) | 368.19M | 306.54M | 260.01M | 194.24M | 179.91M |
Currency in SEK
